Quinn Opportunity Partners LLC Makes New Investment in Novo Nordisk A/S $NVO

Key Points

• Quinn Opportunity Partners LLC initiated a new stake in Novo Nordisk, acquiring 226,000 shares worth about $12.54 million, equal to 0.9% of the firm's portfolio and making NVO its 24th-largest holding.
• Other large investors materially increased exposure—Franklin Resources now holds ~13.98M shares after adding ~13.66M, Capital International owns ~17.71M after adding ~6.09M, and Boston Partners opened a new ~$310M position—while institutional ownership is reported at 11.54%.
• Novo is under regulatory and legal pressure: an FDA warning about unreported semaglutide adverse events, a Pomerantz class-action/investigation and multiple analyst downgrades have pressured the stock and left the consensus analyst rating at "Hold" (average target ~$49.93).

Quinn Opportunity Partners LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 226,000 shares of the company's stock, valued at approximately $12,541,000. Novo Nordisk A/S comprises 0.9% of Quinn Opportunity Partners LLC's investment portfolio, making the stock its 24th biggest holding.

A number of other large investors also recently modified their holdings of the stock. Franklin Resources Inc. grew its holdings in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company's stock worth $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Capital International Investors lifted its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company's stock valued at $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Boston Partners purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $310,199,000. SG Americas Securities LLC boosted its holdings in Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company's stock worth $132,242,000 after acquiring an additional 2,274,925 shares during the last quarter. Finally, DAVENPORT & Co LLC grew its stake in shares of Novo Nordisk A/S by 54.8% in the 3rd quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company's stock worth $146,644,000 after acquiring an additional 935,468 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Analysts Set New Price Targets

Several brokerages have recently commented on NVO. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. BMO Capital Markets restated a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. The Goldman Sachs Group reissued a "neutral" rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $49.93.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $37.99 on Friday. The company has a market capitalization of $169.61 billion, a P/E ratio of 10.95 and a beta of 0.73. The company's 50-day moving average is $50.14 and its 200 day moving average is $51.79. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $82.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.